title: [Clinical and laboratory evaluation of the efficiency of chronic hemodialysis treatment using acidosuccinate in patients with terminal renal failure].
abstract: OBJECTIVE
  To evaluate the efficiency of using a succinate-containing dialysis solution (SCDS) in terminal renal failure patients treated with chronic hemodialysis (CHD).
  
  
  METHODS
  Ninety patients from two hemodialysis units took part in the crossover study and were allocated to 2 groups. For 6 months, study group patients received CHD using SCDS and control group patients had CHD with a standard bicarbonate dialysis solution after 3-month washout period followed by decussation. The time course of changes in blood biochemical parameters, 24-hour ECG monitoring data, and quality of life indicators were estimated in the patients.
  
  
  RESULTS
  After using acidosuccinate during hemodialysis, there was a significant reduction in the predialysis serum level of inorganic phosphate, a calcium phosphate product, gamma-glutamyl transpeptidase, urea, and aldosterone as compared to the control group. The blood concentration of total protein was also increased. After 6-month administration of acidosuccinate, the patients showed reductions in systolic blood pressure, heart rate, and the frequency and duration of ST-segment depression episodes. There were positive changes in the quality of life of patients according to the KDQOL-SF questionnaire.
  
  
  CONCLUSIONS
  The use of SCDS in patients with CHD causes positive changes in a number of laboratory parameters and improves the physical and general status, and quality of life of patients.
authors.forename: A V
authors.initials: AV
authors.lastname: Smirnov
authors.forename: O B
authors.initials: OB
authors.lastname: Nesterova
authors.forename: E D
authors.initials: ED
authors.lastname: Suglobova
authors.forename: R V
authors.initials: RV
authors.lastname: Golubev
authors.forename: A N
authors.initials: AN
authors.lastname: Vasil'ev
authors.forename: I A
authors.initials: IA
authors.lastname: Vasil'eva
authors.forename: E V
authors.initials: EV
authors.lastname: Verbitskaia
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Korosteleva
authors.forename: E M
authors.initials: EM
authors.lastname: Kostereva
authors.forename: E B
authors.initials: EB
authors.lastname: Lebedeva
authors.forename: E N
authors.initials: EN
authors.lastname: Levykina
authors.forename: K G
authors.initials: KG
authors.lastname: Starosel'skiĭ
authors.forename: V A
authors.initials: VA
authors.lastname: Lazeba
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood*; D018592:Cross-Over Studies; D015314:Dialysis Solutions / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D006435:Renal Dialysis / Q000379:methods*; D019802:Succinic Acid / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D015415:Biomarkers; D015314:Dialysis Solutions; D019802:Succinic Acid